Search results
Results from the WOW.Com Content Network
Non-ergoline dopamine receptor agonists have higher binding affinity to dopamine D 3-receptors than dopamine D 2-receptors. This binding affinity is related to D 2 and D 3 receptor homology, the homology between them has a high degree of sequence and is closest in their transmembrane domains, were they share around 75% of the amino acid. [37]
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.
Dopamine receptors are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling. Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. [2]
Some dopamine receptors are located in the walls of arteries, where they act as a vasodilator and an inhibitor of norepinephrine release from postganglionic sympathetic nerves terminals (dopamine can inhibit norepinephrine release by acting on presynaptic dopamine receptors, and also on presynaptic α-1 receptors, like norepinephrine itself). [75]
A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia , bipolar disorder , and stimulant psychosis . [ 1 ]
The researchers found the mechanisms that make dopamine receptors a risk factor. The mechanism exists specifically in a subtype of the dopamine receptor, called the autoreceptor, which regulates ...
Dopamine receptor antagonists can be divided into D 1-like receptor antagonists and D 2-like receptor antagonists. Ecopipam is an example of a D 1 -like receptor antagonist. At low doses, dopamine D 2 and D 3 receptor antagonists can preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and thereby increase dopamine levels and ...
Bromocriptine is a partial agonist of the dopamine D 2 receptor. [ 21 ] [ 22 ] [ 23 ] It also interacts with other dopamine receptors and with various serotonin and adrenergic receptors . [ 21 ] [ 22 ] [ 24 ] Bromocriptine has additionally been found to inhibit the release of glutamate by reversing the GLT1 glutamate transporter .